Seppo Yla-Herttuala MD, PhD

Ex-Officio


Prof. Seppo Yla-Herttuala MD, PhD is Professor of Molecular Medicine for A.I. Virtanen Institute for Molecular Sciences and Department of Medicine, University of Kuopio, Kuopio, Finland. Dr. Yla-Herttuala is an Internationally Recognized Leader in cardiovascular gene therapy.

His team was among the first to use adenovirus-mediated gene transfer in human arteries and since then, he has conducted several clinical trials in cardiovascular gene therapy. His group is also widely recognized for basic and applied biology research related to vascular endothelial growth factors, especially with newer members of the growth factor family. Dr. Ylä-Herttuala was one of Ark Therapeutics Group plc's co-founders in 1997.

He has been Member of Scientific Advisory Board of Cardium Therapeutics Inc., since November 11, 2006. Dr. Yla-Herttuala served as a Non-Executive Director of ARK Therapeutics Group PLC from March 8, 2004 to May 15, 2013. He serves on the editorial boards of several major US and European cardiovascular and gene therapy journals. He has published over 250 scientific papers and articles related to cardiovascular diseases, VEGFs, Atherosclerosis, rest enosis and gene therapy.

Board & Officers

The ASGCT Board of Directors and the Society's officers have full responsibility for the management, direction and control of the Society.

2019
22nd Annual Meeting
April 29 – May 2 | Washington D.C.
Close